Abeona Therapeutics Company Profile (OTCMKTS:ACCP)

About Abeona Therapeutics (OTCMKTS:ACCP)

Abeona Therapeutics logoAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ACCP
  • CUSIP: N/A
  • Web: abeonatherapeutics.com/
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Dividend Yield: 1.0%
  • Net Margins: -3,815.21%
  • Return on Equity: -35.94%
  • Return on Assets: -32.89%

Frequently Asked Questions for Abeona Therapeutics (OTCMKTS:ACCP)

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the OTCMKTS under the ticker symbol "ACCP."

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:

  • Steven H. Rouhandeh, Executive Chairman of the Board
  • Timothy J. Miller Ph.D., President, Chief Executive Officer, Director
  • Jeffrey B. Davis, Chief Operating Officer
  • David P. Nowotnik Ph.D., Senior Vice President - Research and Development
  • Harrison G. Wehner III, Senior Vice President - Plasma
  • Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary
  • Michelle Berg, Vice President - Communications & Operations
  • Andre'a Lucca, Vice President - Communications & Operations
  • Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
  • Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of Abeona Therapeutics stock can currently be purchased for approximately $0.22.

MarketBeat Community Rating for Abeona Therapeutics (OTCMKTS ACCP)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (OTCMKTS:ACCP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Abeona Therapeutics (OTCMKTS:ACCP)
Price Target History for Abeona Therapeutics (OTCMKTS:ACCP)
Analysts' Ratings History for Abeona Therapeutics (OTCMKTS:ACCP)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for Abeona Therapeutics (OTCMKTS:ACCP)
No earnings announcements for this company have been tracked by MarketBeat.com


Earnings Estimates for Abeona Therapeutics (OTCMKTS:ACCP)
Current Year EPS Consensus Estimate: $0.70 EPS


Dividend History for Abeona Therapeutics (OTCMKTS:ACCP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Abeona Therapeutics (OTCMKTS:ACCP)
No insider trades for this company have been tracked by MarketBeat.com


Headline Trends for Abeona Therapeutics (OTCMKTS:ACCP)
Latest Headlines for Abeona Therapeutics (OTCMKTS:ACCP)
Loading headlines, please wait.



Abeona Therapeutics (ACCP) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.